In the News
TransEnterix Names John Tushar Vice President of Business Development
RESEARCH TRIANGLE PARK, N.C. – John R. Tushar has been named vice president of business development at TransEnterix.
Tushar, a veteran executive of the medical-device industry, joined TransEnterix in 2008. In his new capacity, he is responsible for managing all of TransEnterix’s business-development activities, including international partnerships and licensing agreements.
TransEnterix is preparing to launch a revolutionary multi-channel laparoscopic surgical platform called the SPIDER™ System. Short for Single Port Instrument Delivery Extended Reach, the SPIDER System represents one of the more promising advances in technology that the field of laparoscopic surgery has experienced in many years. TransEnterix anticipates marketing its platform in early 2010.
Previously, Tushar served as director of worldwide market development and strategy for Closure Medical Corp, a division of Ethicon Inc., and as a global strategist and business development executive for Ethicon Endo-Surgery. Both are multi-billion-dollar divisions of Johnson & Johnson.
He also served as interim chief executive officer of RemeDease Inc., an early-stage medical-device company that spun out of the University of North Carolina at Chapel Hill Kenan-Flagler Business School’s entrepreneurship program.
“John has deep knowledge and extensive experience in business development, which is important for our success as our company brings a new medical device to market in the highly competitive field of minimally invasive surgery,” said Todd M. Pope, president and CEO.
TransEnterix is an emerging medical-device company that partners with the world’s leading surgeons to develop pioneering technologies that revolutionize minimally invasive surgery. It relies on rapid prototyping, intense pre-clinical labs and hands-on collaboration with expert surgeons to accelerate learning and bring a device to market more quickly.
The company recently secured $55 million during a second round of institutional financing. TransEnterix has secured a total of $75 million in venture capital funding since its inception in 2006.
To learn more about TransEnterix, visit www.transenterix.com. To learn more about the SPIDER System and to see how it works, visit www.spidersurgery.com.